Vimarsana
Biggest News Aggregation in the World

Page 29 - Mc Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mc Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mc Services Today - Breaking & Trending Today

EQS-News: Carbios aims to be a leader in growing r-PET market with an ambition to capture 8 to 12% share by 2035 through licensing model - Vimarsana News

EQS-News: Carbios aims to be a leader in growing r-PET market with an ambition to capture 8 to 12% share by 2035 through licensing model

EQS-News: Carbios SA / Key word(s): Miscellaneous Carbios aims to be a leader in growing r-PET market with an ambition to capture 8 to 12% share by 2035 through licensing model 06.06.2023 / 06:45 CET/CEST The issuer is solely responsible for the content of this announcement. Carbios aims to be a...

Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals Announces Publication of New Preclinical Data Showing Durable Antitumor Activity of LNAplus-Based ASOs that Both Stimulate the Innate Immune System and Suppress PD-L1 Expression - Vimarsana News

Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals Announces Publication of New Preclinical Data Showing Durable Antitumor Activity of LNAplus-Based ASOs that Both Stimulate the Innate Immune System and Suppress PD-L1 Expression

Compelling in vivo and in vitro data published in peer-reviewed Journal for ImmunoTherapy of Cancer (JITC)Secarna's LNAplus-based ASOs effectively stimulate TLR9 signaling, an important innate immune pathway

EQS-News: Apogenix AG: Apogenix' new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model - Vimarsana News

EQS-News: Apogenix AG: Apogenix' new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model

EQS-News: Apogenix AG / Key word(s): Scientific publication Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model 01.06.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Apogenix’ new CD40 agonist...

Rentschler Biopharma joins forces with Ikarovec to - Vimarsana News

Rentschler Biopharma joins forces with Ikarovec to

Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage,...

EQS-News: Mainz Biomed Expands Commercial Footprint into Poland - Vimarsana News

EQS-News: Mainz Biomed Expands Commercial Footprint into Poland

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous Mainz Biomed Expands Commercial Footprint into Poland 31.05.2023 / 09:0...